drugset / Trial / NCT00685919

Peripheral Dopamine in Postural Tachycardia Syndrome

NCT00685919

Phase 2/3 Completed 32 enrolled Vanderbilt University
RandomizedCrossoverSingle-blindOther

Summary

The purpose of the proposed research is to determine how changes in kidney dopamine (DA) activity influence urinary sodium excretion. We will decrease DA activity in the kidney by inhibiting DA synthesis via carbidopa administration. We want to compare findings in normal volunteers and in patients with postural tachycardia syndrome (POTS). We will test the null hypothesis (Ho) that the effects of oral carbidopa administration on urinary sodium excretion will not differ between patients with POTS and healthy volunteers.

Timeline

Start
2008-05
Primary completion
2020-07
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 200 mg Oral